Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
J Bone Miner Res ; 38(12): 1822-1833, 2023 12.
Article in English | MEDLINE | ID: mdl-37823782

ABSTRACT

Cherubism is a rare autosomal dominant disease characterized by expansile osteolytic jawbone lesions. The effect and safety of off-label calcitonin treatment during the progressive phase of the disease are not well described. In this retrospective study, we present data on the radiological response and adverse effects of subcutaneously administered calcitonin in a cohort of nine cherubism children (three female, six male). Two of the nine patients underwent two separate treatment courses with a significant off-treatment interval in between; therefore, a total of 11 treatment courses with a mean duration of 17.9 months (range <1 to 35, SD 10.8) were studied. To measure the response, the cumulative volume of cherubism lesions was calculated from available three-dimensional imaging. The primary outcome was the change in the volume of lesions during calcitonin treatment and only assessed for the eight treatment courses with a minimal duration of 6 months. A statistically significant reduction in the mean cumulative volume of lesions was seen regardless of treatment duration. Average volume reduction was highest in the first half year of treatment, with a gradual, ongoing reduction thereafter. For the secondary outcome, the change in the cumulative volume of lesions after treatment cessation was assessed for the seven treatment courses with follow-up imaging available. After six of these seven treatment courses, the cumulative volume increased again but remained undoubtedly smaller than the initial volume at the start of therapy. Adverse effects were assessed for all 11 treatment courses and occurred in 73% of them. Most adverse effects were mild and low grade, with the most severe being one grade 3 symptomatic hypocalcemia requiring hospitalization and early treatment termination. Calcitonin treatment seems effective and tolerable in treating actively progressing cherubism in children. However, further research is required to better understand the pharmacological treatment of cherubism, including also other drugs, dosing, and protocols. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).


Subject(s)
Calcitonin , Cherubism , Child , Humans , Male , Female , Calcitonin/adverse effects , Cohort Studies , Cherubism/drug therapy , Retrospective Studies , Minerals
2.
J Craniomaxillofac Surg ; 51(10): 591-596, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37852890

ABSTRACT

The aim of our study was to review current concepts in targeted therapies for benign tumors of the jaw. Benign odontogenic and maxillofacial bone tumors often require radical surgery, with consequent morbidity that impacts patients' postsurgical quality of life. Currently, targeted therapies and novel nonsurgical therapeutics are being explored for management of non-resectable tumors, with the aim of avoiding surgery or minimizing surgical scope. However, data on clinical applications of targeted therapies for benign tumors of the jaw remain sparse. Therefore, a literature review was conducted, based on the PubMed database, which included in vivo human clinical studies describing clinical application of targeted therapy for benign tumor of the jaw. The review assessed the outcomes of BRAF and MEK inhibitors for treatment of ameloblastoma, RANKL monoclonal antibody for treatment of giant cell tumor, cherubism, aneurysmal bone cyst, and fibrous dysplasia, and tyrosine kinase inhibitor for treatment of odontogenic myxoma and cherubism. Targeted therapies decreased tumor size, slowed down tumor progression, and reduced bone pain. Surgery remains the gold standard, but targeted therapies are promising adjuvant or alternative treatment options for reducing tumor progression and morbidity of tumor surgery.


Subject(s)
Ameloblastoma , Cherubism , Jaw Neoplasms , Odontogenic Tumors , Humans , Jaw Neoplasms/drug therapy , Jaw Neoplasms/surgery , Cherubism/drug therapy , Quality of Life , Odontogenic Tumors/pathology , Ameloblastoma/pathology
3.
Front Endocrinol (Lausanne) ; 14: 1104025, 2023.
Article in English | MEDLINE | ID: mdl-36998472

ABSTRACT

Objective: The aim of this systematic review was to determine if there exists an efficacious drug treatment for cherubism, based on published studies. Methods: This systematic review included observational case studies reporting pharmacological management of cherubism. We developed specific search strategies for PubMed (including Medline), ScienceDirect, Web of Science. We evaluated the methodological quality of the included studies using criteria from the Joanna Briggs Institute's critical appraisal tools. Results: Among the 621 studies initially identified by our search script, 14 were selected for inclusion, of which five were classified as having a low risk of bias, four as having an unclear risk, and five a high risk. Overall, 18 cherubism patients were treated. The sample size in each case study ranged from one to three subjects. This review identified three types of drugs used for cherubism management: calcitonin, immunomodulators and anti-resorptive agents. However, the high heterogeneity in case reports and the lack of standardized outcomes precluded a definitive conclusion regarding the efficacy of any treatment for cherubism. Conclusions: The present systematic review could not identify an effective treatment for cherubism due to the heterogeneity and limitations of the included studies. However, in response to these shortcomings, we devised a checklist of items that we recommend authors consider in order to standardize the reporting of cherubism cases and specifically when a treatment is given toward identification of an efficacious cherubism therapy. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351044, identifier CRD42022351044.


Subject(s)
Cherubism , Humans , Cherubism/drug therapy , Treatment Outcome
4.
Cleft Palate Craniofac J ; 60(12): 1665-1673, 2023 12.
Article in English | MEDLINE | ID: mdl-35821585

ABSTRACT

Cherubism is a rare disorder characterized by proliferative fibro-osseous lesions that result in bilateral bony hyperplasia of the face. Management varies based on symptom severity and includes longitudinal follow-up, pharmacotherapy, and/or surgical debulking. Off-label treatment with denosumab, a human monoclonal antibody that binds RANKL and inhibits osteoclast function to reduce bone resorption, can be beneficial in suppressing the proliferation of bone to minimize the need for surgery and to control postoperative reproliferation. Close follow-up is needed to maintain appropriate electrolyte levels. The present case demonstrates the achievement of symptomatic control with denosumab in a child with severe refractory cherubism.


Subject(s)
Cherubism , Child , Humans , Cherubism/drug therapy , Cherubism/surgery , Denosumab/therapeutic use , Mandible/surgery , Maxilla/surgery
5.
Oral Dis ; 29(3): 1089-1101, 2023 Apr.
Article in English | MEDLINE | ID: mdl-34743383

ABSTRACT

OBJECTIVE: Cherubism is a genetic disorder characterised by bilateral jawbone deformation. The associated jawbone lesions regress after puberty, whereas severe cases require surgical treatment. Although several drugs have been tested, fundamental treatment strategies for cherubism have not been established. The effectiveness of imatinib has recently been reported; however, its pharmaceutical mechanism remains unclear. In this study, we tested the effects of imatinib using a cherubism mouse model. METHODS: We used Sh3bp2 P416R cherubism mutant mice, which exhibit systemic organ inflammation and osteopenia. The effects of imatinib were determined using primary bone marrow-derived macrophages. Imatinib was administered intraperitoneally to the mice, and serum tumour necrosis factor-α (TNFα), organ inflammation and bone properties were examined. RESULTS: The cherubism mutant macrophages produced higher levels of TNFα in response to lipopolysaccharide compared to wild-type macrophages, and imatinib did not significantly suppress TNFα production. Although imatinib suppressed osteoclast formation in vitro, administering it in vivo did not suppress organ inflammation and osteopenia. CONCLUSION: The in vivo administration of imatinib had a minimal therapeutic impact in cherubism mutant mice. To establish better pharmaceutical interventions, it is necessary to integrate new findings from murine models with clinical data from patients with a definitive diagnosis of cherubism.


Subject(s)
Bone Diseases, Metabolic , Cherubism , Mice , Animals , Cherubism/drug therapy , Cherubism/genetics , Tumor Necrosis Factor-alpha/metabolism , Imatinib Mesylate/pharmacology , Imatinib Mesylate/therapeutic use , Adaptor Proteins, Signal Transducing/genetics , Inflammation/pathology , Phenotype
6.
J Oral Maxillofac Surg ; 79(3): 598-607, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33159843

ABSTRACT

Cherubism is a rare disease of the jaws characterized by bilateral symmetrical painless expansion of the mandible and maxilla. In extreme cases, larger lesions can become exophytic and have profound functional and esthetic implications. Several pharmacologic agents have been trialed in the treatment of cherubism with variable success reported. Bisphosphonates have not been significantly studied in this setting. We present a case where oral alendronic acid was used as an adjuvant treatment after surgical debulking of the maxilla in a 13-year-old boy with a severe case of cherubism.


Subject(s)
Cherubism , Adolescent , Cherubism/diagnostic imaging , Cherubism/drug therapy , Humans , Male , Mandible , Maxilla/diagnostic imaging , Maxilla/surgery
7.
J Pediatr Endocrinol Metab ; 33(7): 963-966, 2020 Jul 28.
Article in English | MEDLINE | ID: mdl-32649295

ABSTRACT

Background Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand, which strongly suppresses osteoclasts. Cherubism is a rare autosomal dominant disorder characterized by symmetrical swelling of the jaws, in which the bone is replaced by a fibrous granuloma containing osteoclast-like giant cells. Case presentation We report the efficacy and safety of denosumab treatment in a prepubertal boy with progressive cherubism. The treatment consisting of eight subcutaneous denosumab injections (120 mg/dose) in 6 months not only suppressed the expansion of the osteolytic lesions but also dramatically ossified them. However, a transiently decreased growth rate and rebounded asymptomatic hypercalcemia were associated with the treatment. Conclusions The present case demonstrated the therapeutic potential of denosumab for treatment of cherubism, although adverse effects, especially those on childhood growth, remain obscure. Further studies are needed to establish a safe and effective protocol for denosumab treatment of children.


Subject(s)
Cherubism/drug therapy , Denosumab/therapeutic use , Cherubism/pathology , Child , Child, Preschool , Disease Progression , Humans , Japan , Male , Puberty/drug effects , Puberty/physiology , Treatment Outcome
8.
J Oral Maxillofac Surg ; 78(12): 2226-2234, 2020 12.
Article in English | MEDLINE | ID: mdl-32649899

ABSTRACT

Cherubism is a rare autosomal dominant disease whose severity ranges widely, from asymptomatic to life-threatening. Bilateral symmetrical painless expansion of the mandible and maxilla resulting in a typical appearance of the face resembling a cherub, are the highlighted features of the condition. In most cases, cherubism-induced lesions in the jaws appear around the age of 3 years and tend to expand and increase in numbers until puberty. Treatment options for cherubism range from observation to surgical correction and various pharmacologic therapies. Given the excess sensitivity of cherubism osteoclasts to RANKL (receptor activator of nuclear factor κB ligand) and the positive effects of denosumab (XGEVA; Amgen, Thousand Oaks, CA) treatment in patients with giant cell granuloma, we have designed a treatment based on denosumab for 2 cherubism patients that achieves what we consider promising results.


Subject(s)
Cherubism , Denosumab , Cherubism/drug therapy , Denosumab/therapeutic use , Humans , Mandible , Maxilla , Patients
9.
J Oral Maxillofac Surg ; 77(6): 1278.e1-1278.e7, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30880133

ABSTRACT

Cherubism is an autosomal-dominant inherited mutation in the SH3BP2 gene on chromosome 4p16.3. It is characterized by bilateral symmetric fibro-osseous lesions that are limited to the maxilla and mandible. The lesions present in early childhood and typically spontaneously involute after puberty. Current standard practice is to reserve surgery for symptomatic or severely disfiguring cases. This report presents 3 patients with cherubism who exhibited marked reduction in tumor size with imatinib, a tyrosine kinase inhibitor. Treatment was well tolerated, with few side effects.


Subject(s)
Antineoplastic Agents , Cherubism , Imatinib Mesylate , Tooth , Adaptor Proteins, Signal Transducing/genetics , Antineoplastic Agents/therapeutic use , Cherubism/drug therapy , Child , Child, Preschool , Humans , Imatinib Mesylate/therapeutic use , Mandible , Maxilla
10.
J Bone Miner Res ; 33(8): 1513-1519, 2018 08.
Article in English | MEDLINE | ID: mdl-29669173

ABSTRACT

Cherubism is a craniofacial disorder characterized by maxillary and mandibular bone destruction. Gain-of-function mutations in the SH3-domain binding protein 2 (SH3BP2) are responsible for the excessive bone resorption caused by fibrous inflammatory lesions. A homozygous knock-in (KI) mouse model for cherubism (Sh3bp2KI/KI ) develops autoinflammation resulting in systemic bone destruction. Although administration of the TNF-α blocker etanercept to neonatal Sh3bp2KI/KI mice prevented the disease onset, this therapy was not effective for adult Sh3bp2KI/KI mice or human cherubism patients who already had lesions. Because genetic ablation of spleen tyrosine kinase (SYK) in myeloid cells rescues Sh3bp2KI/KI mice from inflammation, we examined whether SYK inhibitor administration can improve fully developed cherubism symptoms in adult Sh3bp2KI/KI mice. Entospletinib (GS-9973) was intraperitoneally injected into 10-week-old Sh3bp2KI/KI mice every day for 6 weeks. Treatment with GS-9973 improved facial swelling and histomorphometric analysis of lung and liver tissue showed that GS-9973 administration significantly reduced inflammatory infiltrates associated with decreased levels of serum TNF-α. Micro-computed tomography (µCT) analysis showed that GS-9973 treatment reduced bone erosion in mandibles, calvariae, and ankle and elbow joints of Sh3bp2KI/KI mice compared to Sh3bp2KI/KI mice treated with dimethyl sulfoxide (DMSO). Taken together, the results demonstrate that administration of the SYK inhibitor ameliorates an already established cherubism phenotype in mice, suggesting that pharmacological inhibition of SYK may be a treatment option for cherubism patients with active disease progression. © 2018 American Society for Bone and Mineral Research.


Subject(s)
Bone and Bones/pathology , Cherubism/drug therapy , Indazoles/therapeutic use , Inflammation/drug therapy , Protein Kinase Inhibitors/therapeutic use , Pyrazines/therapeutic use , Syk Kinase/antagonists & inhibitors , Adaptor Proteins, Signal Transducing/metabolism , Animals , Bone and Bones/drug effects , Cherubism/complications , Disease Models, Animal , Indazoles/administration & dosage , Indazoles/pharmacology , Inflammation/complications , Inflammation/pathology , Mice , Protein Kinase Inhibitors/pharmacology , Pyrazines/administration & dosage , Pyrazines/pharmacology , Syk Kinase/metabolism
11.
Bone ; 111: 28-35, 2018 06.
Article in English | MEDLINE | ID: mdl-29530719

ABSTRACT

We utilized a bone marrow stromal culture system to investigate changes in TGFß signaling in a mouse model for cherubism (Sh3bp2KI/KI). Interestingly, bone marrow cultures derived from cherubism mice not only displayed impaired osteoblast differentiation, but also had spontaneous osteoclast formation. PAI1, a target gene of TGFß signaling, was elevated 2-fold in cherubism CD11b-,CD45- cells compared to wild type cells, while the expression of BAMBI, an inhibitor of TGFß signaling, was down-regulated. We also discovered that treatment of cherubism cultures with antagonists of the TGFß signaling pathway could largely rescue osteoblast differentiation and markedly reduce spontaneous osteoclast formation. Treatment with the type I TGFß receptor small molecule inhibitor SB505124 increased osteoblast reporter gene Col1a1-2.3 expression 24-fold and increased the expression of osteoblast gene markers Osterix (Sp7) 25-fold, Bone Sialoprotein (BSP) 7-fold, Osteocalcin (Bglap1) 100-fold, and Dentin Matrix Protein 1 (DMP1) 35-fold. In contrast, SB505124 treatment resulted in a significant reductions in osteoclast number and size. Gene expression analyses for RANKL, a positive regulator of osteoclast formation was 2.5-fold higher in osteoblast cultures derived from Sh3bp2KI/KI mice compared to wild type cultures, whereas OPG, an inhibitor of RANKL was 5-fold lower. However, SB505124 treatment reduced RANKL almost back down to wild type levels, while increasing OPG expression. Our studies also implicate a role for TGFß ligands in the etiology of cherubism. Blocking of TGFß ligands with the monoclonal antibody 1D11 increased Col1a1-2.3 reporter expression 4-fold and 13-fold in cultures derived from Sh3bp2KI/+ and Sh3bp2KI/KI mice, respectively. Serum levels of latent TGFß1 were also 2-fold higher in SH3BP2KI/KI mice compared to wild type littermates. Taken together, these studies provide evidence that elevated levels of TGFß signaling may contribute to the disease phenotype of cherubism and a reduction in pathway activity may be an effective therapeutic approach to treat this rare disease.


Subject(s)
Benzodioxoles/therapeutic use , Cherubism/drug therapy , Cherubism/pathology , Imidazoles/therapeutic use , Pyridines/therapeutic use , Transforming Growth Factor beta/antagonists & inhibitors , Adaptor Proteins, Signal Transducing/genetics , Animals , Benzodioxoles/pharmacology , Bone Marrow Cells/cytology , Bone Resorption , Cell Differentiation/genetics , Cells, Cultured , Disease Models, Animal , Femur/cytology , Genetic Markers/genetics , Imidazoles/pharmacology , Membrane Proteins/genetics , Mice , Molecular Targeted Therapy , Osteoblasts/cytology , Osteoclasts/cytology , Osteogenesis , Phenotype , Pyridines/pharmacology , RANK Ligand/genetics , Stromal Cells , Tibia/cytology , Transforming Growth Factor beta/physiology
13.
J Bone Miner Res ; 30(5): 878-85, 2015 May.
Article in English | MEDLINE | ID: mdl-25491283

ABSTRACT

Cherubism is a rare genetic disorder characterized by extensive growth of a bilateral granuloma of the jaws, resulting in facial disfigurement. Cherubism is caused by gain-of-function mutations in the SH3BP2 gene, leading to overactivation of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)-dependent osteoclastogenesis. Recent findings in human and mouse cherubism have suggested that calcineurin inhibitors might be drug candidates in cherubism medical treatment. A 4-year-old boy with aggressive cherubism was treated with the calcineurin inhibitor tacrolimus for 1 year, and clinical, radiological, and molecular data were obtained. Immunohistologic analysis was performed to compare preoperative and postoperative NFATc1 staining and tartrate resistant acid phosphatase (TRAP) activity. Real-time PCR was performed to analyze the relative expression levels of OPG and RANKL. After tacrolimus therapy, the patient showed significant clinical improvement, including stabilization of jaw size and intraosseous osteogenesis. Immunohistologic analyses on granuloma showed that tacrolimus caused a significant reduction in the number of TRAP-positive osteoclasts and NFATc1 nuclear staining in multinucleated giant cells. Molecular analysis showed that tacrolimus treatment also resulted in increased OPG expression. We present the first case of effective medical therapy in cherubism. Tacrolimus enhanced bone formation by stimulating osteogenesis and inhibiting osteoclastogenesis.


Subject(s)
Calcineurin Inhibitors/therapeutic use , Cherubism/drug therapy , Tacrolimus/therapeutic use , Acid Phosphatase/metabolism , Calcineurin Inhibitors/pharmacology , Cell Count , Cherubism/diagnostic imaging , Child, Preschool , Humans , Isoenzymes/metabolism , Male , Models, Biological , NFATC Transcription Factors/metabolism , Osteoclasts/drug effects , Osteoclasts/pathology , Osteogenesis/drug effects , Osteoprotegerin/metabolism , RANK Ligand/metabolism , Radiography , Tacrolimus/pharmacology , Tartrate-Resistant Acid Phosphatase
14.
J Bone Miner Res ; 29(5): 1170-82, 2014.
Article in English | MEDLINE | ID: mdl-24978678

ABSTRACT

Cherubism is a genetic disorder of the craniofacial skeleton caused by gain-of-function mutations in the signaling adaptor protein, SH3-domain binding protein 2 (SH3BP2). In a knock-in mouse model for cherubism, we previously demonstrated that homozygous mutant mice develop T/B cell-independent systemic macrophage inflammation leading to bone erosion and joint destruction. Homozygous mice develop multiostotic bone lesions whereas cherubism lesions in humans are limited to jawbones. We identified a critical role of tumor necrosis factor α (TNF-α) in the development of autoinflammation by creating homozygous TNF-α-deficient cherubism mutants, in which systemic inflammation and bone destruction were rescued. In this study, we examined whether postnatal administration of an anti-TNF-α antagonist can prevent or ameliorate the disease progression in cherubism mice. Neonatal homozygous mutants, in which active inflammation has not yet developed, were treated with a high dose of etanercept (25 mg/kg, twice/week) for 7 weeks. Etanercept-treated neonatal mice showed strong rescue of facial swelling and bone loss in jaws and calvariae. Destruction of joints was fully rescued in the high-dose group. Moreover, the high-dose treatment group showed a significant decrease in lung and liver inflammatory lesions. However, inflammation and bone loss, which were successfully treated by etanercept administration, recurred after etanercept discontinuation. No significant effect was observed in low-dose-treated (0.5 mg/kg, twice/week) and vehicle-treated groups. In contrast, when 10-week-old cherubism mice with fully active inflammation were treated with etanercept for 7 weeks, even the high-dose administration did not decrease bone loss or lung or liver inflammation. Taken together, the results suggest that anti-TNF-α therapy may be effective in young cherubism patients, if treated before the inflammatory phase or bone resorption occurs. Therefore, early genetic diagnosis and early treatment with anti-TNF-α antagonists may be able to prevent or ameliorate cherubism, especially in patients with a mutation in SH3BP2.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Bone Diseases, Metabolic/drug therapy , Bone Diseases, Metabolic/metabolism , Cherubism/drug therapy , Cherubism/metabolism , Immunoglobulin G/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Adaptor Proteins, Signal Transducing/genetics , Animals , Bone Diseases, Metabolic/genetics , Bone Diseases, Metabolic/pathology , Cherubism/genetics , Cherubism/pathology , Etanercept , Gene Knock-In Techniques , Humans , Inflammation , Mice , Mice, Mutant Strains , Receptors, Tumor Necrosis Factor , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics
15.
Bone ; 52(1): 347-53, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23069372

ABSTRACT

Cherubism is a rare and disfiguring genetic disorder with excessive bone resorption and multilocular lesions in the mandible and/or maxilla. The disease-causing gain-of-function mutations in the SH3-binding protein 2 (SH3BP2) gene result in increased myeloid cell responses to macrophage colony stimulating factor and RANK ligand, formation of hyperactive osteoclasts (giant cells), and hyper-reactive macrophages that produce excessive amounts of the inflammatory cytokine tumor necrosis factor α (TNF-α). Recent findings in the cherubism mouse model suggest that TNF-α plays a major role in disease pathogenesis and that removal of TNF-α prevents development of the bone phenotype. We treated two children with cherubism with the TNF-α antagonist adalimumab for approximately 2.5 years and collected extensive clinical, radiological and histological follow-up data during the treatment. Histologically the treatment resulted in a significant reduction in the number of multinucleated giant cells and TNF-α staining positivity in both patients. As evaluated by computed tomography and magnetic resonance imaging, the lesions in Patient 1 showed either moderate enlargement (mandibular symphysis) or remained stable (mandibular rami and body, the maxilla). In Patient 2, the lesions in mandibular symphysis showed enlargement during the first 8 months of treatment, and thereafter the lesions remained unchanged. Bone formation and resorption markers remained unaffected. The treatment was well tolerated. Based on our findings, TNF-α antagonist may decrease the formation of pathogenic giant cells, but does not result in lesion regression or prevent lesion expansion in active cherubism. TNF-α modulator treatment thus does not appear to provide sufficient amelioration for patients suffering from cherubism.


Subject(s)
Cherubism/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adaptor Proteins, Signal Transducing/genetics , Animals , Cherubism/diagnostic imaging , Cherubism/genetics , Cherubism/pathology , Child, Preschool , Disease Models, Animal , Female , Humans , Male , Mice , Radiography
19.
Ned Tijdschr Geneeskd ; 144(1): 34-8, 2000 Jan 01.
Article in Dutch | MEDLINE | ID: mdl-10665301

ABSTRACT

Cherubism was diagnosed in a male when he was 6 years old. Cherubism is a benign, bilateral, painless lesion. It is commonly located in the mandible but in a minority of patients also in the maxilla. Cherubism is a familial condition with an autosomal dominant pattern of inheritance. At least one member of the family of the patient described had cherubism. The disease becomes manifest during early childhood and progresses until puberty when it spontaneously regresses. In the majority of patients no treatment is required. However, in the patient presented surgical procedures and odontological corrections were necessary. Due to a flare-up of the disease at the age of 22 years, the patient was treated with calcitonin for 1 year followed by bisphosphonates. During these treatments the disease symptoms diminished.


Subject(s)
Cherubism/diagnosis , Cherubism/therapy , Adult , Calcitonin/therapeutic use , Cherubism/drug therapy , Cherubism/genetics , Cherubism/surgery , Child , Diagnosis, Differential , Diphosphonates/therapeutic use , Genetic Predisposition to Disease , Granuloma, Giant Cell/diagnosis , Humans , Male , Mandible/drug effects , Mandible/surgery , Oral Surgical Procedures , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...